NASDAQ:URGN
UroGen Pharma Ltd Stock News
$14.96
-0.210 (-1.38%)
At Close: Mar 27, 2024
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
08:13pm, Thursday, 14'th Mar 2024
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
10:10am, Thursday, 14'th Mar 2024
Urogen Pharma (URGN) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $1.22 per share a year ago.
Urogen Pharma Ltd (URGN) Q3 2023 Earnings Call Transcript
02:59pm, Tuesday, 14'th Nov 2023
Urogen Pharma Ltd (URGN) Q3 2023 Earnings Call Transcript
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
02:49pm, Friday, 18'th Aug 2023
This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet
11:30am, Thursday, 10'th Aug 2023
The consensus price target hints at an 89.6% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
10:46am, Thursday, 10'th Aug 2023
Urogen Pharma (URGN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.18 per share a year ago.
Why Shares of UroGen Pharma Jumped Friday
01:41pm, Friday, 28'th Jul 2023
UroGen also announced a $120 million private placement to raise funds. The company said it could have its second marketed product as early as next year.
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
10:42am, Thursday, 16'th Mar 2023
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma to Present at Upcoming Investor Conferences
04:00pm, Wednesday, 01'st Mar 2023
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen: Struggling With Revenue And With Cash Runway
04:04am, Wednesday, 08'th Feb 2023
UroGen has an approved drug and a platform. However, there's not much growth in revenue.
UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain
01:30pm, Monday, 21'st Nov 2022
Shares have lost nearly two-thirds of their value over the past 3 years. RTGel platform is a great fit for bladder cancers due to its ability to allow molecules to reside in the target space for an ex
UroGen Pharma Ltd. (URGN) Q3 2022 Earnings Call Transcript
12:05pm, Thursday, 10'th Nov 2022
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director-Investor Relations Liz Barrett - President & Chi
Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last?
06:01am, Wednesday, 12'th Oct 2022
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter
Urogen Pharma Ltd (URGN) CEO Elizabeth Barrett on Q2 2022 Results - Earnings Call Transcript
02:48pm, Thursday, 11'th Aug 2022
Urogen Pharma Ltd (NASDAQ:URGN ) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director, IR Elizabeth Barrett - President, CEO & Director M
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call Transcript
04:35pm, Tuesday, 10'th May 2022
UroGen Pharma Ltd. (NASDAQ:URGN ) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director of IR Liz Barrett - President and CEO Mark Schoenberg